专利检索 cpc:"A61K35/37" 第 12 页

111.

发明申请
COMPOSITIONS AND METHODS 有权

公开(公告)号：US20170196914A1

公开(公告)日：2017-07-13

申请号：US15415745

申请日：2017-01-25

申请人： SERES THERAPEUTICS, INC.

发明人： Gregory McKenzie , Mary-Jane Lombardo McKenzie , David N. Cook , Marin Vulic , Geoffrey von Maltzahn , Brian Goodman , John Grant Aunins , Matthew R. Henn , David Arthur Berry , Jonathan Winkler

IPC分类号： A61K35/742 , A61K45/06 , A61K9/00 , A61K9/48 , A61K35/37

CPC分类号： A61K35/741 , A61K9/0053 , A61K9/48 , A61K9/4816 , A61K35/37 , A61K35/74 , A61K35/742 , A61K35/744 , A61K35/745 , A61K35/747 , A61K45/06 , C12N1/20 , Y02A50/402 , Y02A50/469 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/48 , Y02A50/481

摘要： Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.

112.

发明授权
Extracellular matrix encasement structures and methods 有权

公开(公告)号：US09682171B2

公开(公告)日：2017-06-20

申请号：US14833354

申请日：2015-08-24

申请人： CorMatrix Cardiovascular, Inc.

发明人： Robert G Matheny

IPC分类号： A61F13/00 , A61K35/12 , A61K35/34 , A61L33/00 , A61L27/36 , A61L31/00 , A61L27/38 , A61F2/00 , A61L27/34 , A61F2/02 , A61L27/54 , A61L31/16 , A61L27/50 , A61L31/14 , A61N1/375 , A61L27/22 , A61K35/38 , A61K35/22 , A61F2/24 , A61K38/00 , A61K35/42

CPC分类号： A61L27/3629 , A61F2/0077 , A61F2/02 , A61F2/24 , A61F2002/0086 , A61F2210/0076 , A61K35/12 , A61K35/22 , A61K35/37 , A61K35/38 , A61K35/42 , A61K38/005 , A61K38/1825 , A61L27/227 , A61L27/34 , A61L27/3604 , A61L27/362 , A61L27/3625 , A61L27/3633 , A61L27/3679 , A61L27/3683 , A61L27/38 , A61L27/3804 , A61L27/3834 , A61L27/50 , A61L27/54 , A61L31/005 , A61L31/041 , A61L31/14 , A61L31/16 , A61L2300/20 , A61L2300/23 , A61L2300/25 , A61L2300/252 , A61L2300/40 , A61L2300/404 , A61L2300/406 , A61L2300/41 , A61L2300/412 , A61L2300/414 , A61L2300/418 , A61L2300/434 , A61L2300/45 , A61L2300/64 , A61L2400/02 , A61L2400/12 , A61L2400/18 , A61L2430/20 , A61N1/375 , A61N1/3752

摘要： A bioremodelable encasement structure comprising a pouch formed from at least one sheet of bioremodelable material, the pouch including an internal region that is configured to receive a device therein, the bioremodelable material comprising mesothelial tissue.

113.

发明授权
Probiotic recolonisation therapy 有权

公开(公告)号：US09682108B2

公开(公告)日：2017-06-20

申请号：US15260207

申请日：2016-09-08

申请人： Crestovo LLC

发明人： Thomas Julius Borody

IPC分类号： A01N63/00 , A01N65/00 , A61K39/08 , A61K35/742 , A61K35/74 , A61K38/48 , A61K35/741 , A61K35/744 , A61K35/747 , A61K36/062 , A61K45/06 , A61K38/14 , A61K31/341 , A61K31/41 , A61K31/495 , A61K31/7034 , A23L2/52 , A61K35/745 , A61K35/38 , A61K35/24 , A61K9/00 , A23C9/123 , A61K9/48 , A23C9/13 , A23L33/135 , A23C9/127 , A61K9/19 , A61K35/37 , A61K31/545 , A61K39/00 , A61K35/76 , A61K31/43 , A61K38/00 , A61K31/7048 , A61K9/50 , A61K39/39 , A61K51/12 , A61K35/00

CPC分类号： A61K35/742 , A23C9/123 , A23C9/127 , A23C9/13 , A23L2/52 , A23L33/135 , A23V2002/00 , A61K9/0031 , A61K9/0053 , A61K9/19 , A61K9/48 , A61K9/4891 , A61K9/50 , A61K9/5005 , A61K9/5078 , A61K31/341 , A61K31/41 , A61K31/43 , A61K31/495 , A61K31/545 , A61K31/7034 , A61K31/7048 , A61K35/24 , A61K35/37 , A61K35/38 , A61K35/74 , A61K35/741 , A61K35/744 , A61K35/745 , A61K35/747 , A61K35/76 , A61K36/062 , A61K38/00 , A61K38/14 , A61K38/4893 , A61K39/00 , A61K39/39 , A61K45/06 , A61K51/1217 , A61K2035/115 , C12N2795/00032 , Y02A50/401 , Y02A50/469 , Y02A50/473 , A61K2300/00

摘要： The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.

114.

发明授权
Extracellular matrix encasement structures and methods 有权

公开(公告)号：US09669133B2

公开(公告)日：2017-06-06

申请号：US14833404

申请日：2015-08-24

申请人： CorMatrix Cardiovascular, Inc.

发明人： Robert G Matheny

IPC分类号： A61F2/00 , A61K35/37 , A61K35/12 , A61L33/00 , A61L27/36 , A61L31/00 , A61L27/38 , A61L27/34 , A61F2/02 , A61L27/54 , A61L31/16 , A61L27/50 , A61L31/14 , A61N1/375 , A61L27/22 , A61K35/38 , A61K35/22 , A61F2/24 , A61K38/00 , A61K35/42

CPC分类号： A61L27/3629 , A61F2/0077 , A61F2/02 , A61F2/24 , A61F2002/0086 , A61F2210/0076 , A61K35/12 , A61K35/22 , A61K35/37 , A61K35/38 , A61K35/42 , A61K38/005 , A61K38/1825 , A61L27/227 , A61L27/34 , A61L27/3604 , A61L27/362 , A61L27/3625 , A61L27/3633 , A61L27/3679 , A61L27/3683 , A61L27/38 , A61L27/3804 , A61L27/3834 , A61L27/50 , A61L27/54 , A61L31/005 , A61L31/041 , A61L31/14 , A61L31/16 , A61L2300/20 , A61L2300/23 , A61L2300/25 , A61L2300/252 , A61L2300/40 , A61L2300/404 , A61L2300/406 , A61L2300/41 , A61L2300/412 , A61L2300/414 , A61L2300/418 , A61L2300/434 , A61L2300/45 , A61L2300/64 , A61L2400/02 , A61L2400/12 , A61L2400/18 , A61L2430/20 , A61N1/375 , A61N1/3752

摘要： A pouch structure formed from extracellular matrix (ECM) derived from small intestine submucosa (SIS) that includes an internal region configured to receive a medical device therein. The pouch structure is configured to modulate inflammation of damaged biological tissue and induce cell and tissue proliferation, bioremodeling of the damaged biological tissue, and regeneration of tissue structures with site-specific structural and functional properties, when implanted in a subject.

115.

发明授权
Extracellular matrix encasement structures and methods 有权

公开(公告)号：US09662418B2

公开(公告)日：2017-05-30

申请号：US14685755

申请日：2015-04-14

申请人： CorMatrix Cardiovascular, Inc.

发明人： Robert G Matheny

IPC分类号： A61F2/00 , A61K35/37 , A61K35/12 , A61L27/36 , A61L31/00 , A61L27/38 , A61L27/34 , A61F2/02 , A61L27/54 , A61L31/16 , A61L27/50 , A61L31/14 , A61N1/375 , A61L27/22 , A61K35/38 , A61K35/22 , A61F2/24 , A61K38/00 , A61K35/42

CPC分类号： A61L27/3629 , A61F2/0077 , A61F2/02 , A61F2/24 , A61F2002/0086 , A61F2210/0076 , A61K35/12 , A61K35/22 , A61K35/37 , A61K35/38 , A61K35/42 , A61K38/005 , A61K38/1825 , A61L27/227 , A61L27/34 , A61L27/3604 , A61L27/362 , A61L27/3625 , A61L27/3633 , A61L27/3679 , A61L27/3683 , A61L27/38 , A61L27/3804 , A61L27/3834 , A61L27/50 , A61L27/54 , A61L31/005 , A61L31/041 , A61L31/14 , A61L31/16 , A61L2300/20 , A61L2300/23 , A61L2300/25 , A61L2300/252 , A61L2300/40 , A61L2300/404 , A61L2300/406 , A61L2300/41 , A61L2300/412 , A61L2300/414 , A61L2300/418 , A61L2300/434 , A61L2300/45 , A61L2300/64 , A61L2400/02 , A61L2400/12 , A61L2400/18 , A61L2430/20 , A61N1/375 , A61N1/3752

摘要： A bioremodelable encasement structure comprising a pouch formed from at least one sheet of bioremodelable material, the pouch including an internal region that is configured to receive a device therein, the bioremodelable material comprising mesothelial tissue.

116.

发明授权
Probiotic recolonisation therapy 有权

公开(公告)号：US09610308B2

公开(公告)日：2017-04-04

申请号：US15178539

申请日：2016-06-09

申请人： Crestovo LLC

发明人： Thomas Julius Borody

IPC分类号： A61K39/00 , A61K39/38 , A61K39/02 , A61K39/08 , A61K39/108 , A61K35/741 , A61K35/74 , A61K38/48 , A61K35/742 , A61K35/744 , A61K35/747 , A61K36/062 , A61K45/06 , A61K38/14 , A61K31/341 , A61K31/41 , A61K31/495 , A61K31/7034 , A23L2/52 , A61K35/745 , A61K35/38 , A61K35/24 , A61K9/00 , A23C9/123 , A61K9/48 , A23C9/13 , A23L33/135 , A23C9/127 , A61K31/545 , A61K35/76 , A61K31/43 , A61K38/00 , A61K31/7048 , A61K9/50 , A61K39/39 , A61K51/12 , A61K35/00

CPC分类号： A61K35/742 , A23C9/123 , A23C9/127 , A23C9/13 , A23L2/52 , A23L33/135 , A23V2002/00 , A61K9/0031 , A61K9/0053 , A61K9/19 , A61K9/48 , A61K9/4891 , A61K9/50 , A61K9/5005 , A61K9/5078 , A61K31/341 , A61K31/41 , A61K31/43 , A61K31/495 , A61K31/545 , A61K31/7034 , A61K31/7048 , A61K35/24 , A61K35/37 , A61K35/38 , A61K35/74 , A61K35/741 , A61K35/744 , A61K35/745 , A61K35/747 , A61K35/76 , A61K36/062 , A61K38/00 , A61K38/14 , A61K38/4893 , A61K39/00 , A61K39/39 , A61K45/06 , A61K51/1217 , A61K2035/115 , C12N2795/00032 , Y02A50/401 , Y02A50/469 , Y02A50/473 , A61K2300/00

摘要： The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.

117.

发明申请
PROBIOTIC RECOLONISATION THERAPY 有权

公开(公告)号：US20160375068A1

公开(公告)日：2016-12-29

申请号：US15260207

申请日：2016-09-08

申请人： Crestovo LLC

发明人： Thomas Julius BORODY

IPC分类号： A61K35/742 , A61K35/37 , A61K35/741 , A61K35/747 , A61K35/745 , A61K9/00 , A61K9/19

CPC分类号： A61K35/742 , A23C9/123 , A23C9/127 , A23C9/13 , A23L2/52 , A23L33/135 , A23V2002/00 , A61K9/0031 , A61K9/0053 , A61K9/19 , A61K9/48 , A61K9/4891 , A61K9/50 , A61K9/5005 , A61K9/5078 , A61K31/341 , A61K31/41 , A61K31/43 , A61K31/495 , A61K31/545 , A61K31/7034 , A61K31/7048 , A61K35/24 , A61K35/37 , A61K35/38 , A61K35/74 , A61K35/741 , A61K35/744 , A61K35/745 , A61K35/747 , A61K35/76 , A61K36/062 , A61K38/00 , A61K38/14 , A61K38/4893 , A61K39/00 , A61K39/39 , A61K45/06 , A61K51/1217 , A61K2035/115 , C12N2795/00032 , Y02A50/401 , Y02A50/469 , Y02A50/473 , A61K2300/00

摘要： The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.

118.

发明申请
PROBIOTIC RECOLONISATION THERAPY 有权

公开(公告)号：US20160279178A1

公开(公告)日：2016-09-29

申请号：US15178537

申请日：2016-06-09

申请人： Crestovo LLC

发明人： Thomas Julius BORODY

IPC分类号： A61K35/742 , A61K35/741 , A61K9/48 , A61K9/00

CPC分类号： A61K35/742 , A23C9/123 , A23C9/127 , A23C9/13 , A23L2/52 , A23L33/135 , A23V2002/00 , A61K9/0031 , A61K9/0053 , A61K9/19 , A61K9/48 , A61K9/4891 , A61K9/50 , A61K9/5005 , A61K9/5078 , A61K31/341 , A61K31/41 , A61K31/43 , A61K31/495 , A61K31/545 , A61K31/7034 , A61K31/7048 , A61K35/24 , A61K35/37 , A61K35/38 , A61K35/74 , A61K35/741 , A61K35/744 , A61K35/745 , A61K35/747 , A61K35/76 , A61K36/062 , A61K38/00 , A61K38/14 , A61K38/4893 , A61K39/00 , A61K39/39 , A61K45/06 , A61K51/1217 , A61K2035/115 , C12N2795/00032 , Y02A50/401 , Y02A50/469 , Y02A50/473 , A61K2300/00

摘要： The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.